CYP19A1 and breast cancer: Aromatase inhibitors, such as tamoxifen, which was once the gold standard for hormonal breast cancer therapy in postmenopausal women, can cause toxicities such as arthralgia, bone loss, and cognitive dysfunction (30–32).